Bel'skaya Lyudmila V, Sarf Elena A, Kosenok Victor K
Biochemistry Research Laboratory, Omsk State Pedagogical University, 644099 Omsk, Russia.
Department of Oncology, Omsk State Medical University, 644099 Omsk, Russia.
Diagnostics (Basel). 2021 May 20;11(5):912. doi: 10.3390/diagnostics11050912.
The aim of this study was to compare overall survival (OS) rates at different pN stages of NSCLC depending on tumor characteristics and to assess the applicability of saliva biochemical markers as prognostic signs. The study included 239 patients with NSCLC (pN-120, pN-51, pN-68). Saliva was analyzed for 34 biochemical indicators before the start of treatment. For pN, the tumor size does not have a prognostic effect, but the histological type should be taken into account. For pN and pN, long-term results are significantly worse in squamous cell cancer with a large tumor size. A larger volume of surgical treatment reduces the differences between OS. The statistically significant factors of an unfavorable prognosis at pN are the lactate dehydrogenase activity <1294 U/L and the level of diene conjugates >3.97 c.u. (HR = 3.48, 95% CI 1.21-9.85, = 0.01541); at pN, the content of imidazole compounds >0.296 mmol/L (HR = 6.75, 95% CI 1.28-34.57, = 0.00822); at pN levels of protein <0.583 g/L and Schiff bases >0.602 c.u., as well as protein >0.583 g/L and Schiff bases <0.602 c.u. (HR = 2.07, 95% CI 1.47-8.93, = 0.04351). Using salivary biochemical indicators, it is possible to carry out stratification into prognostic groups depending on the lymph node metastasis.
本研究的目的是根据肿瘤特征比较非小细胞肺癌(NSCLC)不同pN分期的总生存率(OS),并评估唾液生化标志物作为预后指标的适用性。该研究纳入了239例NSCLC患者(pN- 120例、pN- 51例、pN- 68例)。在治疗开始前对唾液进行了34种生化指标分析。对于pN,肿瘤大小没有预后影响,但应考虑组织学类型。对于pN和pN,肿瘤体积大的鳞状细胞癌的长期结果明显更差。更大范围的手术治疗可缩小OS之间的差异。pN预后不良的统计学显著因素是乳酸脱氢酶活性<1294 U/L和二烯共轭物水平>3.97 c.u.(HR = 3.48,95%CI 1.21 - 9.85,P = 0.01541);对于pN,咪唑化合物含量>0.296 mmol/L(HR = 6.75,95%CI 1.28 - 34.57,P = 0.00822);对于pN,蛋白质水平<0.583 g/L和席夫碱>0.602 c.u.,以及蛋白质>0.583 g/L和席夫碱<0.602 c.u.(HR = 2.07,95%CI 1.47 - 8.93,P = 0.04351)。利用唾液生化指标,可以根据淋巴结转移情况将患者分层为不同的预后组。